Alle Storys
Folgen
Keine Story von Biocartis mehr verpassen.

Biocartis

Biocartis and Hospital del Mar (Barcelona, Spain) Join Forces to Develop Diagnostic Colon Cancer Test

Spain (ots/PRNewswire)

Today Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer. This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalised therapy.

Innovative platforms and tests for cancer diagnosis

Biocartis is active in molecular diagnostics and develops innovative diagnostic platforms, which allow for efficient disease detection. Biocartis also develops a wide range of clinically relevant tests for various therapeutic areas, with a primary focus on cancer diagnosis.

EGFR: new biomarker for colon cancer

Recently Dr Montagut and her team (Dr Albanell's department of Medical Oncology, Hospital del Mar) showed that colon cancer patients with an S492R-mutation in the EGFR (Epidermal Growth Factor Receptor) can't be helped with the colon cancer drug cetuximab. The EGFR mutation makes the tumours resistant to this treatment, whilst they remain sensitive to treatment with panitumumab. These results were published in the leading scientific journal Nature Medicine.

Rapid diagnosis results in personalised therapy

"Our agreement with Biocartis represents a crucial step in translating our relevant scientific findings to benefit the patient," according to Clara Montagut, associated doctor, Oncology department, Hospital del Mar and researcher at the IMIM (Hospital del Mar Medical Research Institute).

The collaboration with Hospital del Mar enables Biocartis to develop a colon cancer test for a fast and accurate detection of the EGFR mutation. "This new biomarker enables us to develop a unique combination of tests for the detection of colon cancer, which can be analysed on our state-of-the-art molecular diagnostic platforms," added Geert Maertens, Chief Scientific Officer at Biocartis. "The detection of this biomarker in colon cancer patients ensures that personalised therapy can be applied faster and more efficiently."

Contact:

Contact: Geert Maertens, CSO, Phone: +32-15-632-600 (Mechelen),
gmaertens@biocartis.com

Weitere Storys: Biocartis
Weitere Storys: Biocartis
  • 04.09.2013 – 10:02

    Biocartis Strengthens Management Team With Chief Commercial Officer

    Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company, announces today that Ulrik Cordes has joined the company as Chief Commercial Officer (CCO). Ulrik Cordes is an executive with 18+ years of experience in marketing and sales in the med-tech, pharma and biotech industry, of which the past 10 years in top level management roles. "We are delightedtowelcomeUlrik to ...

  • 15.01.2013 – 15:32

    Biocartis Strengthens Management Team with General Counsel Life Sciences and Biotechnology

    Lausanne, Switzerland And Mechelen, Belgium (ots/PRNewswire) - Biocartis, a molecular diagnostics company developing and commercializing innovative, high quality, easy to use platforms and clinically relevant oncology assays, announced today that Inge Basteleurs has joined the company as General Counsel. Inge will be a member of Biocartis' Executive Committee and a ...

  • 12.12.2012 – 14:07

    Biocartis Completes ?34,5 Million ($44,5 Million) Series D Fund Raising

    Lausanne, Switzerland (ots/PRNewswire) - - Capital to be used to commercialize recently launched DMAT platform, validate APOLLO platform and build proprietary oncology content on both platforms - Strong support from internal shareholders and a recognition of our achievements Biocartis, a molecular diagnostics company developing and commercializing innovative, high ...